Can anyone help?
Does anyone know the date of this patent, Has it been granted yet and does the WIPO mean it is an international patent? And if so does it also apply to the US? Behind on my DNAG DD and crazy week ahead. Thanks in advance for any replys
NEWS: DNAPRINT GENOMICS re: WIPO patent:
(WO/2006/053322) COMPOSITIONS AND METHODS FOR INFERRING AN ADVERSE EFFECT IN RESPONSE TO A DRUG TREATMENT
Biblio. DataDescription Claims National PhaseNoticesDocuments
COMPOSITIONS AND METHODS FOR INFERRING AN ADVERSE EFFECT IN RESPONSE TO A DRUG TREATMENT
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
[0001] The invention relates generally to methods for inferring a muscle adverse effect due to treatment with a statin, and more specifically to methods of detecting single nucleotide polymorphisms and combinations thereof in a nucleic acid sample that provide an inference as to whether is likely or not likely to have a muscle adverse effect in response to treatment with a statin.
BACKGROUND INFORMATION
[0002] Heart attacks are the leading cause of death in the United States today. An increased risk of heart attack is linked with abnormally high blood cholesterol levels. Patients with abnormally high cholesterol levels are frequently prescribed a class of drugs called statins to reduce cholesterol levels, thereby reducing the risk of heart attack. However, these drugs are not effective in all patients. Furthermore, in some patients, adverse reactions including muscle adverse effect (e.g., myopathy and rhabdomyolysis). Such an adverse response may require that treatment of a patient be changed or discontinued.
[0003] Variable statin responses likely can be explained, at least in part, by genetic differences of patients. Human beings differ by up to 0.1% of the 3 billion letters of DNA present in the human genome. Though humans are 99.9% identical in genetic sequence, it is the 0.1% that determines the uniqueness of an individual. Though our individuality is apparent from visual inspection - anyone can recognize that we have facial features, heights and colors, and that these features are, to an extent, heritable (i.e. sons and daughters tend to resemble their parents more than strangers) -our individuality extends to less apparent features, including the ability to respond to and metabolize drugs.
[0004] An identification of the precise molecule details responsible for individuality is a challenging task. The human genome project resulted in the sequencing of the human genome. However, this sequencing was the result of sampling taken from a small number of individuals. Therefore, while this sequencing was an important scientific milestone, the initial sequencing of the human genome does not provide adequate information regarding genetic differences between individuals to allow identification of markers on the genome that are responsible for our individuality, particularly whether an individual will respond to statins and, if so, whether adverse effects such as muscle adverse effects are likely to occur. If the genetic markers that were responsible for different statin responses between people were identified, then an individual's genotype for key markers could be determined, and this information could be used by a physician to decide whether to prescribe statins, and which statins to prescribe. Such personalized medicine can improve the response rate in individuals, while, at the same time, reducing adverse reactions. Thus, there is a need for methods and compositions that allow an inference of muscle adverse effects in a subject treated with as statin based on an individual's genotype for key markers.
SUMMARY OF THE INVENTION
[0005] The present invention is based, in part, on the identification of single nucleotide polymorphisms (SNPs) that are associated with adverse effects due to drug treatment. As such, the SNPs provide a tool for personalized medicine in that the identification of one or more SNPs allows an inference to be drawn as to whether a human subject to be treated with a drug, particularly a statin or an angiotensin converting enzyme (ACE) inhibitor is likely to suffer an adverse effect due to treatment with the drug.
[0006] Accordingly, in one embodiment, the present invention relates to a method for inferring a muscle adverse effect statin response of a human subject from a nucleic acid sample of the subject. Such a method can be performed, for example, by identifying, in a nucleic acid sample from the subject, a nucleotide occurrence of at least one statin response-related SNP of a marker as set forth in any of Tables 1, 2, 4, 5, or a combination thereof, whereby the nucleotide occurrence is associated with a muscle adverse effect in response to administration of the statin, thereby inferring the muscle adverse effect statin response of the subject. The muscle adverse effect statin response, which can be detected by a patient describing the symptoms or by measuring creatine kinase (CK) levels in the subject, can be any undesirable muscle or musculoskeletal effect, and can include symptoms varying from mild aching to severe pain, usually in proximal muscle groups, muscle stiffness and weakness, myalgia (usually associated with a 3-10 fold increase in CK levels above normal), myopathy (usually associated with CK levels more than 10 times greater than normal), or rhabdomyolysis (usually associated with CK levels more than 40 times the upper limit of normal).
In certain embodiments, the marker is nucleotides 3911-4379 of SEQ ID NO: 134; nucleotides 31264-31822 of SEQ ID NO: 131; nucleotides 22281-23778 of SEQ ID NO: 143; nucleotides 3482-4414 of SEQ ID NO: 134; e. nucleotides 1895-2286 of SEQ ID NO: 132; nucleotides 650-1166 of SEQ ID NO:131; nucleotides 771-1171 of SEQ ID NO: 142; nucleotides 79999-80360 of SEQ ID NO: 133; nucleotides 31264-31822of SEQ ID NO: 131; nucleotides 2440-2560 of SEQ ID NO: 134; nucleotides 23757-24069 of SEQ ID NO: 131; nucleotides 30438-30711 of SEQ ID NO: 131; nucleotides 23571- 24967 of SEQ ID NO: 131; nucleotides 12971-14510 of SEQ ID NO: 143; nucleotides 26896-27098 of SEQ ID NO: 130; nucleotides 8115-8737 of SEQ ID NO: 143; nucleotides 13465-13865 of SEQ ID NO:138; nucleotides 26056-26456 of SEQ ID NO:138; nucleotides 26167-26197 of SEQ ID NO:138; nucleotides 17636-18035 of SEQ ID NO:138; nucleotides 25354-25754 of SEQ ID NO:138; nucleotides 12153-12553 of SEQ ID NO:138; nucleotides 7082-7942 of SEQ ID NO:139; nucleotides 5779-5827 of SEQ ID NO.-135; nucleotides 5851-6442 of SEQ ID NO:135; nucleotides 7909-8504 of SEQ ID NO:139; nucleotides 651-1166 of SEQ ID NO:131; nucleotides 4351-4750 of SEQ ID NO:139. nucleotides 3138-3500 of SEQ ID NO:139; nucleotides 3482-4414 of SEQ ID NO:131; nucleotides 4397-4797 of SEQ ID NO:139; nucleotides 31264-31813 of SEQ ID NO:131;. nucleotides 16240-16589 of SEQ ID NO:145;. nucleotides 25192- 2298 of SEQ ID NO: 145; nucleotides 11344-12528 of SEQ ID NO: 139; nucleotides 2800-3685 of SEQ ID NO: 129; 30350-30631 of SEQ ID NO: 131; nucleotides 750-1110 • of SEQ ID NO: 134; nucleotides 5880-6229 of SEQ ID NO: 145; nucleotides 25192-25479 of SEQ ID NO: 145;. nucleotides 17794-18106 of SEQ ID NO:130;. nucleotides 26895- 27098 of SEQ ID NO: 130; nucleotides 26895-25478 of SEQ ID NO: 130;. nucleotides 34-825 of SEQ ID NO:127; nucleotides 11012-11412 of SEQ ID NO:135; nucleotides 3178-3786 of SEQ ID NO:134; nucleotides 143-518 of SEQ ID NO:140;nucleotides 17795-18116 of SEQ ID NO: 130; nucleotides 3388-3786 of SEQ ID NO: 134; nucleotides 502-902 of SEQ ID NO: 126; nucleotides 23737-24368 of SEQ ID NO: 131; nucleotides 1805-2204 of SEQ ID NO:131; nucleotides 5841-6441 of SEQ ID NO:135; nucleotides 26613-27098 of SEQ ID NO: 130; nucleotides 19968-20369 of SEQ ID NO: 138; nucleotides 19636-21357 of SEQ ID NO:136; nucleotides 2440-2560 of SEQ ID NO:134; nucleotides 5881-6229 of SEQ ID NO:142; the complement of any of these nucleotide regions.
[0007] In various aspects of the invention, the SNP is located at nucleotide 4332 of SEQ ID NO: 134;nucleotide 31683 of SEQ ID NO: 131; nucleotide 23077 of SEQ ID NO: 143; nucleotide 4208 of SEQ ID NO: 134; nucleotide 2098 of SEQ ID NO: 132; nucleotide 860 of SEQ ID NO:131; nucleotide 971 of SEQ ID NO:142; nucleotide 2098 of SEQ ID NO: 133; nucleotide 80160 SEQ ID NO: 131; nucleotide 2500 of SEQ ID NO: 134; nucleotide 23809 of SEQ ID NO: 131; nucleotide 30635 of SEQ ID NO: 131; nucleotide 24272 of SEQ ID NO: 131; nucleotide 13780 of SEQ ID NO: 143; nucleotide 296935 of SEQ ID NO: 130; nucleotide 8462 of SEQ ID NO: 143; nucleotide 13665 of SEQ ID NO:138; nucleotide 26256 of SEQ ID NO:138; nucleotide 26137 of SEQ ID NO:138; nucleotide 17836 of SEQ ID NO:138; nucleotide 25554 of SEQ ID NO:138; nucleotide 12353 of SEQ ID NO:138; nucleotide 7444 of SEQ ID NO:139; nucleotide 5832 of SEQ ID NO: 135; nucleotide 6063 of SEQ ID NO: 135; nucleotide 8004 of SEQ ID NO:139; nucleotide 860 of SEQ ID NO:131; nucleotide 4550 of SEQ ID NO:139; nucleotide 3300 of SEQ ID NO:139; nucleotide 4208 of SEQ ID NO:131; nucleotide 4597 of SEQ ID NO:139; nucleotide 31671 of SEQ ID NO:131; nucleotide 16399 of SEQ ID NO: 145; nucleotide 2097 of SEQ ID NO: 145; nucleotide 11987 of SEQ ID NO: 139; nucleotide 3500 of SEQ ID NO: 129; nucleotide 30434 of SEQ ID NO: 131; nucleotide 930 of SEQ ID NO: 134; nucleotide 6046 of SEQ ID NO: 145; nucleotide 25286 of SEQ ID NO:145; nucleotide 18060 of SEQ ID NO:130; nucleotide 26950 of SEQ ID NO:130; nucleotide 26950 of SEQ ID NO: 130; nucleotide 734 of SEQ ID NO: 127; nucleotide 11212 of SEQ ID NO:135; nucleotide 3671 of SEQ ID NO:134; nucleotide 326 of SEQ ID NO:140; nucleotide 18060 of SEQ ID NO:130; nucleotide 3671 of SEQ ID NO:134; nucleotide 702 of SEQ ID NO:126; nucleotide 24205 of SEQ ID NO:131; nucleotide 2005 of SEQ ID NO: 131; nucleotide 6063 of SEQ ID NO: 135; nucleotide 26806 of SEQ ID NO: 130; nucleotide 20169 of SEQ ID NO: 138; nucleotide 20343 of SEQ ID NO: 136; nucleotide 6183 of SEQ ID NO: 142 orjiucleotide 2500 of SEQ ID NO: 134.
[0008] A method of identifying a nucleotide occurrence of at least one statin response- related SNP can be performed, for example, by incubating the nucleic acid sample with a probe or primer that selectively hybridizes to or near a nucleic acid molecule comprising the nucleotide occurrence of the S]NuP, and detecting selective hybridization of the primer or probeT 'Sele'dtϊve hybridization tt^ example, by performing a primer extension reaction, and-detecting a primer extension re
AI
